DXCMDexcom
Price
+11%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growing in the filings, the market undecided.
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Dexcom (DXCM) reported revenue of $1.31B in Q2 2026 (quarter ended Jun 30, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 63% and net income of $249M (19% of revenue). For the full year FY2025, revenue was $4.66B (+16% year on year) and net income $836M. Its largest region in Q2 2026 was United States at $894M, 81% of the disclosed total, well ahead of Non Us at 19%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 14, 2026On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.Director or officer change · Form 8-K
- Sep 10, 2026On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.Director or officer change · Form 8-K
- Jul 30, 2026Dexcom Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $1.10BThe company’s own SEC segment disclosure.
- United States$893.5M81%
- Non Us$208.9M19%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
The closest names by size in the same industry